French immunotherapy company TxCell has teamed up with Inserm Transfert, the tech transfer subsidiary of the French National Institute of Health and Medical Research Inserm, to develop immuno-suppressive regulatory T cells.
UK researchers have identified a highly conserved target structure that can be directed to rush dividing cancer cells into premature division and cell death.
Merck KGaA has expanded its portfolio of blood-based RAS diagnostics for use in patient stratification. After kicking off testing with Sysmex Inostics’ CE-marked OncoBEAM RAS CRC liquid biopsy assay last year, the German drug maker welcomed the launch of a second blood-based test to detect KRAS mutations in patients with colorectal cancer (CRC): Biocartis’ Idylla ctKRAS Mutation Assay.
Euronext Brussels-noted adipose stem cell player TiGenix NV wants to offer 2.75 million American Depositary Shares (ADS) in an IPO at Nasdaq Global Market representing 55 million of its ordinary shares which had went up from €0.91 yesterday to €0.96 (10.a.m.).
Roches US subsidiary Genentech has acquired an exclusive option to commercialise Novimmune’s TLR4 antibody NI-0101, the very first personalised approach to treat rheumatoid arthritis. The compound has already proved safety and drugability in a Phase I dose escalation trail.
Viennese Apeptico Forschung und Entwicklung GmbH and Milan-based Mediolanum Farmaceutici S.p.A. have signed a research & development cooperation and license agreement for Apepticos compound solnatide.
For the second time, biotech communication start-up Labiotech hosted its event LBRefresh, this year in Paris, France. Participants enjoyed panel discussions, a start-up battle and intimate fireside chats…
EU consumers have minor knowledge on bioplastics but unrealistically high expectations that can not be fulfilled, researchers said at 11th European Bioplastics Conference in Berlin.
French Carbios has presented a process that depolymerises one of the most common non-recycled plastics polluting the oceans.
French immunotherapy expert Neovacs has teamed up with CDMO 3P Biopharmaceuticals for the manufacture of interferon alpha with recently licensed technology.